
MATRIX METALLOPROTEINASE-2 (MMP-2 )
AND-9 (MMP-9) GENE VARIANTS AND MICROVASCULAR
COMPLICATIONS IN TYPE 2 DIABETES PATIENTS Andjelic Jelic M٭ˡ, Radojkovic D², Nikolic A², Rakicevic Lj², Babic T², Jelic D³, Lalic NM⁴ *Corresponding Author: Marina Andjelic Jelic, Department of Endocrinology, Diabetes and Metabolic
Diseases, Clinical Medical Centre Zvezdara, Dimitrija Tucovica 161, 11000 Belgrade, Serbia, Phone +381 64 122 2010 Fax +381 11 3088733, E mail: drmajelic@gmail.com page: 6
|
MATERIAL AND METHODS
Study design, time and place
This study contained 102 subjects with type 2 diabetes
who were at the Zvezdara University Medical Center from
February 2016 to April 2018. The diagnosis of DM was
established using the criteria of the World Health Organization
(WHO). The presence of microvascular diabetes
complications was investigated in all patients on the basis of
medical history, laboratory analysis and physical examination.
Detailed ophthalmological examination and fundoscopy
were done in order to confirm retinal changes due to
diabetes. Classification was done to distinguish between
nonproliferative retinopathy and proliferative retinopathy.
The diagnosis of nephropathy was established based on
urine albumin excretion in 24h urine. The cut off value was
30 mg/24h. A comprehensive diabetic foot examination
comprising of visual inspection, monofilament examination,
pinprick sensation, and ankle reflexes was performed in
order to establish the diagnosis of diabetic polyneuropathy.
The control group was comprised of 56 healthy subjects
who were recruited during their regular annual health
assessments. The local Ethics Committee gave permission
to conduct the study and each participant signed informed
consent.
Variable
Apart from demographic variables (gender and age),
additional information regarding the duration of diabetes,
antidiabetic medications, and smoking history was collected.
Anthropometric variables included measurements
of height, weight, and body mass index (BMI). The BMI
was calculated according to the following formula: BMI
(kg/m2) ꞊ body weight (kg)/ height (m2).
Metabolic variables included measurements of fasting
blood glucose (FBG), total cholesterol, high density lipoprotein
cholesterol, low density lipoprotein cholesterol, total
triglycerides, serum creatinine, and glycosylated hemoglobin
(HbA1c). Peripheral blood samples were taken from
the patients with type 2 diabetes and the control subjects
after overnight fasting for at least 8 hours and metabolic
parameters were analyzed using the biochemical analyzer
Olimpus AU680. Detection of the MMP-2 and MMP-9
gene variants was performed using polymerase chain a
reaction-restriction fragment length polymorphism (PCRRFLP)
analysis [34]. The region containing the MMP-2
variant -1306C>T was amplified using a forward primer
5’-CTTCCTAGGCTGGTCCTTACTGA-3’ and a reverse
primer 5’-CTGAGACCTGAAGAGCTAAAGAGCT-3’.
The region containing the MMP-9 variant -1562C>T was
amplified using a forward primer 5’-GCCTGGCACAT-AGTAGGCCC-3’ and a reverse primer 5’-CTTCCTAGCCAGCCGGCATC-
3’. Amplification of both regions was
performed by PCR reaction directly from blood using
the following program: 3 cycles at 98°C for 5 min and
55°C for 3 min; 95°C for 5 min; 35 cycles at 95°C for
30 sec; 58°C for 45 sec; and 72°C for 45 sec; and 72°C
for 10 min. The PCR products obtained with primers for
MMP-2 (193bp) were incubated with the restriction endonuclease
BfaI (Thermo Scientific, Waltham, MA, USA)
at 37°C overnight, resulting in either a 193bp fragment
containing the -1306C allele or 164bp and 29bp fragments
in the presence of the -1306T allele. The PCR products
obtained with primers for MMP-9 (436bp) were incubated
with the restriction endonuclease SphI (Thermo Scientific,
Waltham, MA, USA) at 37°C overnight, resulting in a
436bp fragment containing the -1562C allele or 194bp
and 242bp fragments in the presence of the -1562T allele.
Alleles were separated on agarose gel electrophoresis
and visualized with ethidium-bromide staining and UV
transillumination.
|
|
|
|



 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|